Liberty Wealth Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,494
Closed -$95K 606
2021
Q3
$95K Buy
1,494
+750
+101% +$47.7K 0.03% 300
2021
Q2
$46K Buy
744
+6
+0.8% +$365 0.02% 337
2021
Q1
$44K Hold
738
0.02% 301
2020
Q4
$44K Hold
738
0.02% 298
2020
Q3
$40K Buy
738
+3
+0.4% +$162 0.02% 264
2020
Q2
$38K Buy
735
+3
+0.4% +$151 0.03% 260
2020
Q1
$33K Buy
732
+3
+0.4% +$151 0.03% 269
2019
Q4
$39K Buy
729
+87
+14% +$4.29K 0.03% 296
2019
Q3
$30K Sell
642
-117
-15% -$5.6K 0.03% 323
2019
Q2
$38K Buy
759
+123
+19% +$6.08K 0.03% 294
2019
Q1
$32K Buy
636
+3
+0.5% +$149 0.02% 274
2018
Q4
$29K Buy
+633
New +$32.4K 0.02% 273

Other funds holding IHE

Liberty Wealth Management's IHE Position: Q4 2021 in Review

Liberty Wealth Management sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2021, closing a stake of 1,494 shares — an estimated $95K sold.

Liberty Wealth Management first reported a position in IHE in Q4 2018 and held it in 12 quarters. The position peaked at $95K in Q3 2021. 112 funds tracked by Wall St. Rank hold IHE as of Q4 2021.

  • Liberty Wealth Management reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2021 after selling out during the quarter.
  • Liberty Wealth Management sold 1,494 iShares US Pharmaceuticals ETF shares in Q4 2021, an estimated $95K.
  • Liberty Wealth Management first reported a position in iShares US Pharmaceuticals ETF in Q4 2018 and held it in 12 quarters.
  • Liberty Wealth Management's iShares US Pharmaceuticals ETF position peaked at $95K in Q3 2021.
  • 112 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2021.

Based on Liberty Wealth Management's 13F filing for Q4 2021, filed 15 Feb 2022.